Candel Therapeutics Reported CAN-2409 Prostate Cancer Data

New study results show that the immunotherapy treatment reduced the risk of cancer recurrence or death by 41 percent.

Updated on Sept. 30, 2026 in Cancer

Isometric editorial illustration showing spherical immune units surrounding a dense organic mass, symbolizing an immune-stimulating cancer treatment. — Candel Therapeutics announced that its immunotherapy treatment CAN-2409, when combined with radiation, reduced the risk of prostate cancer recurrence or death by 41 percent. AI Illustration. Upload story photo >

Live Poll

Do you believe positive clinical trial results make now a good time to invest in biotech?

Candel Therapeutics announced that its experimental therapy, CAN-2409, significantly improved outcomes for prostate cancer patients in a Phase 3 study. The treatment, when combined with radiation therapy, showed a 41 percent reduction in the risk of recurrence or death compared to radiation alone.

Why it matters

This immunotherapy approach works by directly injecting the agent into tumors to trigger cell death, which then activates the patient's own immune system to target abnormal cells. The data suggests these immune-stimulating effects can persist for more than two years following treatment.

A Phase 3 study demonstrated that CAN-2409 reduced the risk of prostate cancer recurrence or death by 41 percent. Researchers also used AI-based analysis to confirm increased lymphocyte presence in tumors compared to radiation alone.

The players

Candel Therapeutics

This biotechnology company focuses on developing viral immunotherapies for cancer treatment.

The details

The treatment is administered via direct tumor injection to initiate a systemic immune response. Beyond the prostate cancer trial, the company is also testing CAN-2409 for non-small cell lung cancer and is evaluating a separate candidate, Linoserpaturev, for high-grade glioma.

June 2026: Candel held $201.6 million in cash.
September 30, 2026: The company unveiled new trial data.
Q4 2026: A Biologics License Application submission to the FDA is planned.
Q1 2028: Candel expects its current cash reserves to be exhausted.

The Big Picture

This development represents a critical progression toward the FDA's Biologics License Application review process. The trial data serves as the primary evidence supporting the upcoming regulatory filing for CAN-2409.

Patients may eventually gain access to a new immunotherapy option designed to trigger a lasting immune response against tumors. While these results are promising, treatment remains in clinical testing phases and is not currently available for general clinical use.

The takeaway

The study highlights how combining targeted direct-tumor injections with standard radiation therapy can enhance long-term immune system engagement. Patients and providers should monitor the company's progress through the upcoming regulatory phase before clinical implementation.